Charles Schwab Investment Management Inc. Has $4.58 Million Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Charles Schwab Investment Management Inc. grew its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 1.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 823,222 shares of the medical technology company’s stock after purchasing an additional 15,577 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Alphatec were worth $4,577,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its stake in shares of Alphatec by 65.2% in the second quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock valued at $33,365,000 after buying an additional 1,260,137 shares during the period. Magnetar Financial LLC bought a new position in shares of Alphatec in the 2nd quarter worth about $10,957,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Alphatec by 23.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,630,244 shares of the medical technology company’s stock worth $27,486,000 after acquiring an additional 505,202 shares in the last quarter. Granite Investment Partners LLC increased its position in Alphatec by 130.2% in the 2nd quarter. Granite Investment Partners LLC now owns 664,201 shares of the medical technology company’s stock valued at $6,941,000 after buying an additional 375,621 shares in the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in Alphatec in the 3rd quarter valued at about $2,057,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Performance

NASDAQ ATEC opened at $9.62 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a 50-day simple moving average of $7.98 and a two-hundred day simple moving average of $8.15. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -7.52 and a beta of 1.38. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $17.34.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ATEC shares. Lake Street Capital cut their price target on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Thursday, October 31st. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Friday, August 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Alphatec in a report on Thursday, October 31st. Finally, Barclays upped their target price on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.